Abstract:Background This study aimed to determine whether community-acquired pneumonia (CAP) had a metabolic profile and whether this profile can be used for disease severity assessment. Methods A total of 175 individuals including 119 CAP patients and 56 controls were enrolled and divided into two cohorts. Serum samples from a discovery cohort ( n = 102, including 38 non-severe CAP, 30 severe CAP, and 34 age and sex-matched controls) were determined by untargeted ultra-high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS)-based metabolomics. Selected differential metabolites between CAP patients versus controls, and between the severe CAP group versus non-severe CAP group, were confirmed by targeted mass spectrometry assays in a validation cohort ( n = 73, including 32 non-severe CAP, 19 severe CAP and 22 controls). Pearson’s correlation analysis was performed to assess relationships between the identified metabolites and clinical severity of CAP. The area under the curve (AUC), sensitivity and specificity of the metabolites for predicting the severity of CAP were also investigated. Results The metabolic signature was markedly different between CAP patients and controls. Fifteen metabolites were found to be significantly dysregulated in CAP patients, which were mainly mapped to the metabolic pathways of sphingolipid, arginine, pyruvate and inositol phosphate. The alternation trends of five metabolites among the three groups including sphinganine, p-Cresol sulfate, dehydroepiandrosterone sulfate (DHEA-S), lactate and l -arginine in the validation cohort were consistent with those in the discovery cohort. Significantly lower concentrations of sphinganine, p-Cresol sulfate and DHEA-S were observed in CAP patients than in controls ( p < 0.05). Serum lactate and sphinganine levels were positively correlated with confusion, urea level, respiratory rate, blood pressure, and age > 65 years (CURB-65), pneumonia severity index (PSI) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, while DHEA-S inversely correlated with the three scoring systems. Combining lactate, sphinganine and DHEA-S as a metabolite panel for discriminating severe CAP from non-severe CAP exhibited a better AUC of 0.911 (95% confidence interval 0.825–0.998) than CURB-65, PSI and APACHE II scores. Conclusions This study demonstrates that serum metabolomics approaches based on the LC-MS/MS platform can be applied as a tool to reveal metabolic changes during CAP and establish a metabolite signature related to disease severity. Trial registration ClinicalTrials.gov, NCT03093220 . Registered retrospectively on 28 March 2017.

Metabolite profile of COVID-19 revealed by UPLC-MS/MS-based widely targeted metabolomics

The Serum Metabolome of COVID-19 Patients is Distinctive and Predictive

Systematic Discovery and Pathway Analyses of Metabolic Disturbance in COVID-19

Metabolomic Profile for the Early Detection of Coronary Artery Disease by Using UPLC-QTOF/MS.

Metabolomic analyses reveal new stage-specific features of COVID-19

Sera Metabolomics Characterization of Patients at Different Stages in Wuhan Identifies Critical Biomarkers of COVID-19

Plasma metabolomic and lipidomic alterations associated with COVID-19

Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Metabolomic alterations in the plasma of patients with various clinical manifestations of COVID-19

Metabolic profiles in community-acquired pneumonia: developing assessment tools for disease severity

Plasma Metabolomic Profiling of Patients Recovered From Coronavirus Disease 2019 (COVID-19) With Pulmonary Sequelae 3 Months After Discharge

Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts

Quantitative LC-MS study of compounds found predictive of COVID-19 severity and outcome

Combining Semi-Targeted Metabolomics and Machine Learning to Identify Metabolic Alterations in the Serum and Urine of Hospitalized Patients with COVID-19

Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage

Serum metabolomics profile identifies patients with community-acquired pneumonia infected by bacteria, fungi, and viruses

Novel potential metabolic biomarker panel for early detection of severe COVID-19 using full-spectrum metabolome and whole-transcriptome analyses

Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19

Metabolic predictors of COVID-19 mortality and severity: a survival analysis

Metabolite Reanalysis Revealed Potential Biomarkers For Covid-19: A Potential Link With Immune Response